Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Patients Undergoing PCI on Dual Antiplatelet Therapy: A Retrospective Cohort Study - PubMed
a day ago
- #PCI DAPT
- #Retrospective Cohort
- #SSRI Bleeding Risk
- The study investigates the bleeding risk in patients on dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) who also use selective serotonin reuptake inhibitors (SSRIs).
- Using a large real-world cohort, SSRI users on DAPT showed a significantly higher one-year risk of major bleeding (14.0% vs. 11.3%), especially intracranial hemorrhage (1.2% vs. 0.7%) and gastrointestinal bleeding (7.4% vs. 5.6%).
- No significant differences were observed in ischemic outcomes, blood transfusion rates, or all-cause mortality between SSRI users and non-users.
- Higher bleeding risks with SSRIs were more pronounced in older patients and those with hypertension, chronic kidney disease, or NSAID use.
- The findings emphasize the need for clinical awareness of SSRI-related bleeding risks in PCI patients on DAPT, especially in high-risk subgroups.